Third, CXB is proposed to also block the synthesis of IL-6 and prostaglandins, in particular prostaglandin E2 (PGE2), which is the main mediator in BPH (Anderson et al. 1996; Hinson et al. 1996). Here, IL6 is linked to benign prostatic hyperplasia.